

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

<p>1. Name and Address of Reporting Person*</p> <p>SIGMA TAU INTERNATIONAL SA</p> <hr/> <p>(Last) (First) (Middle)</p> <p>18 AVENUE DE LA PORTE NEUVE</p> <hr/> <p>(Street)</p> <p>LUXEMBOURG N4 L-2227</p> <hr/> <p>(City) (State) (Zip)</p>	<p>2. Issuer Name and Ticker or Trading Symbol</p> <p>QUESTCOR PHARMACEUTICALS INC [QSC]</p> <hr/> <p>3. Date of Earliest Transaction (Month/Day/Year)</p> <p>01/12/2004</p> <hr/> <p>4. If Amendment, Date of Original Filed (Month/Day/Year)</p>	<p>5. Relationship of Reporting Person(s) to Issuer (Check all applicable)</p> <p>Director <input checked="" type="checkbox"/> 10% Owner</p> <p>Officer (give title below) Other (specify below)</p> <p>Form filed by One Reporting Person</p> <p><input checked="" type="checkbox"/> Form filed by More than One Reporting Person</p>
--	--	--

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, no par value per share								8,643,397	D	
Common Stock, no par value per share								1,756,781	I	Shares directly held by Claudio Cavazza. ⁽¹⁾
Common Stock, no par value per share								1,756,782	I	Shares directly held by Paolo Cavazza. ⁽¹⁾
Common Stock, no par value per share								1,265,822	I	Shares underlying the Warrants held by Defiante Farmaceutica L.d.A. ⁽¹⁾
Common Stock, no par value per share	01/12/2004		P		759,493	A	\$0.644	759,493	I	Shares directly held by Defiante Farmaceutica L.d.A. ⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Warrant representing the right to buy Common Stock	\$1.7	01/12/2004		S		759,493		03/15/2002	03/15/2006	Common Stock, no par value per share	\$0.07	1,265,822	I	The Warrants are held by Defiante Farmaceutica L.d.A. ⁽¹⁾

1. Name and Address of Reporting Person*

SIGMA TAU INTERNATIONAL SA

(Last) (First) (Middle)

18 AVENUE DE LA PORTE NEUVE

(Street)

LUXEMBOURG N4 L-2227

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[SIGMA TAU FINANZIARIA SPA](#)

(Last) (First) (Middle)

VIA SUDAFRICA 20

144

(Street)

ROME ITALY

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[DEFIANTE FARMACEUTICA LDA](#)

(Last) (First) (Middle)

RUA DOS FERREIROS,260

(Street)

FUNCHAL S1 9000-082
MADEIRA

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[CAVAZZA CLAUDIO](#)

(Last) (First) (Middle)

VIA SUDAFRICA 20

(Street)

ROME ITALY L6 00000

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[CAVAZZA PAOLO](#)

(Last) (First) (Middle)

VIA TESSERETE, 10

(Street)

LUGANO V8 V8

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[APTAFIN S P A](#)

(Last) (First) (Middle)

VIALE SHAKESPEARE 47

(Street)

ROME L6 00144

(City) (State) (Zip)

Explanation of Responses:

1. Sigma-Tau Finanziaria S.p.A. owns 100% of the capital stock of Sigma-Tau International S.A. (f/k/a Sigma-Tau Finance Holding S.A.) and 58% of the capital stock of Defiante Farmaceutica L.d.A. Sigma-Tau International S.A. owns 42% of the capital stock of Defiante Farmaceutica L.d.A. Claudio Cavazza owns, directly and indirectly, 60% of Sigma-Tau Finanziaria S.p.A. and Paolo Cavazza owns, directly and indirectly, 40% of Sigma-Tau Finanziaria S.p.A. Paolo Cavazza also owns, directly and indirectly, 100% of Aptafin S.p.A.

Remarks:

The 759,493 shares of Common Stock, no par value per share, were purchased from Questcor Pharmaceuticals Inc. for total consideration of \$489,113.51, consisting of \$435,949.00 in cash and the surrender of 759,493 warrants held by Defiante Farmaceutica L.d.A. (which were valued at \$53,164.51 upon surrender).

[Maurizio Terenzi, Attorney-in-
fact for Sigma-Tau International S.A.](#) 01/14/2003

[Maurizio Terenzi, Attorney-in-
fact for Sigma-Tau Finanziari S.p.A.](#) 01/14/2003

[Maurizio Terenzi, Attorney-in-
fact for Defiante Farmaceutica L.D.A.](#) 01/14/2003

[Maurizio Terenzi, Attorney-in-fact for Claudio Cavazza](#) [01/14/2003](#)

[Maurizio Terenzi, Attorney-in-fact for Paolo Cavazza](#) [01/14/2003](#)

[Maurizio Terenzi, Attorney-in-fact for Aptafin S.p.A.](#) [01/14/2003](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.